Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cancer patient with metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary initiating a (new) course of chemotherapy with a minimum intent of 3 months therapy~Exclusion Criteria:~* Required systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic;~* High risk of bleeding;~* Severe renal impairment (estimated creatinine clearance \<30 mL/min);~* ECOG (Eastern Cooperative Oncology Group) performance status 3 \& 4;~* Major surgery within 4 weeks before randomization;~* Known hypersensitivity to unfractionated heparin \[UFH\] or low molecular weight heparin \[LMWH\].~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin (Type: EXPERIMENTAL): Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for semuloparin) once daily until change in chemotherapy regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).